Alendronate is contraindicated in patients with esophageal disorders due to the risk of severe esophageal irritation and ulceration.
Contraindicated in esophageal stricture, achalasia, or other motility disorders.
Risk is heightened if patient cannot remain upright for 30 minutes after dosing.
Prompt medical attention for symptoms like difficulty swallowing or chest pain.
Switch to alternatives if bisphosphonates are necessary.
Alendronate, a bisphosphonate, is highly irritating to the esophageal mucosa. In patients with esophageal motility disorders (e.g., strictures, achalasia, or scleroderma), the drug may not transit properly to the stomach, leading to prolonged contact and mucosal damage.
Increased risk of esophagitis, esophageal ulcers, strictures, bleeding, and potentially life-threatening perforation; symptoms include severe dysphagia, odynophagia, chest pain, and retrosternal discomfort.
Contraindicated; avoid alendronate in patients with esophageal abnormalities that delay emptying. Consider alternative osteoporosis treatments like intravenous bisphosphonates or non-bisphosphonate options. If used, ensure upright posture for at least 30 minutes post-dose and monitor closely, though avoidance is recommended.
Was this helpful?
The content on SafeTo is for informational purposes only and does not constitute medical, veterinary, or professional advice. Always consult with a qualified professional for specific concerns.
